Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation
about
Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel DiseaseCD300f associates with IL-4 receptor α and amplifies IL-4-induced immune cell responsesEnhanced efferocytosis by dendritic cells underlies memory T-cell expansion and susceptibility to autoimmune disease in CD300f-deficient miceDisrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment.CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 productionThe expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adultsDendritic cells expressing immunoreceptor CD300f are critical for controlling chronic gut inflammationCeramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation.The CD300e molecule in mice is an immune-activating receptor.Purinergic drug targets for gastrointestinal disorders.CD300 family receptors regulate eosinophil survival, chemotaxis, and effector functions.The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?RAMP1 suppresses mucosal injury from dextran sodium sulfate-induced colitis in mice.A key requirement for CD300f in innate immune responses of eosinophils in colitis.Leukocyte mono-immunoglobulin-like receptor 8 (LMIR8)/CLM-6 is an FcRγ-coupled receptor selectively expressed in mouse tissue plasmacytoid dendritic cells.Gelatin versus its two major degradation products, prolyl‐hydroxyproline and glycine, as supportive therapy in experimental colitis in mice.Structural basis for murine norovirus engagement of bile acids and the CD300lf receptorATP as a Pathophysiologic Mediator of Bacteria-Host Crosstalk in the Gastrointestinal Tract
P2860
Q28073700-CBFF17A9-D39A-456B-A1E9-6100AD9BEEFAQ28509921-BCAABF98-31DD-4AEE-9214-31D4838943E3Q28588565-779478FB-6752-4FB0-B8CB-D41BF60530A1Q33842942-8AB95E8A-4E86-4040-BB3E-C64E49CA21E0Q33918803-658CD99F-9C10-46F8-96AF-EFED7F3E3B89Q37232792-7B5378CE-C1B5-4B7C-AB3F-7608C617C049Q38834628-C2B090B8-D719-4010-9B77-D2182C86C1D4Q41882434-AABBC536-9BDF-47EC-9524-B7B6C055DEFEQ49874464-12E0F2B7-ED96-4532-9DA3-F903533DD7F7Q49918940-3ACA69F9-5F29-432C-9843-AAB21C491196Q49973003-74E89324-27C5-4B06-9904-6040A3BDB6F5Q50202418-E2F57BB0-E23B-455A-97A5-5779E1988F4EQ51577908-1246109B-C98F-4B78-A053-AFFCA81ACB97Q52872953-CF4FEF26-48A1-498A-88FD-7FA29E0D186AQ55208863-D74F07EA-1082-454D-9C06-38ACBC08DD38Q55429567-8DB5EABC-87C5-461E-A4CA-8390CEF22A94Q57107784-C7061CE7-20E0-47B1-BCFC-CB8B88C882DDQ58787642-9D805BEB-00E1-4DB5-B6A1-0A0D32CBC648
P2860
Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@ast
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@en
type
label
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@ast
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@en
prefLabel
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@ast
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@en
P2093
P2860
P3181
P1433
P1476
Ceramide-CD300f binding suppre ...... -mediated mast cell activation
@en
P2093
Akie Maehara
Ayako Kaitani
Ko Okumura
Kumi Izawa
Mariko Takahashi
Masamichi Isobe
Toshihiro Matsukawa
Toshio Kitamura
Yoshinori Yamanishi
P2860
P304
P3181
P356
10.1136/GUTJNL-2014-308900
P407
P577
2016-05-01T00:00:00Z